New daily pill could help breast cancer patients who Can't tolerate standard hormone drugs

NCT ID NCT07541079

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side effects over up to 4.5 years. It is an open-label study, meaning everyone knows they are getting the drug, and there is no placebo or comparison group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: giredestrant (a daily oral drug)
What this could lead to: If it works, this could offer a well-tolerated daily pill option for people with early breast cancer who cannot take standard hormone therapy.
What could go wrong: This is a single-arm, open-label study with no comparison group, so results may be less reliable. Side effects or lack of benefit could still lead to stopping the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY BREAST CANCER

Contacts and locations

Locations

Orange Coast Medical Center
RECRUITING

Fountain Valley, California, 92708-6728, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.